Table 2.
Effects of Currently Approved Technologies on Key Aspects of Management in Patients With Diabetes.
| A1c | Hypoglycemia | Limitations | |
|---|---|---|---|
| CSII |  |
|
1. Cost2. Socioeconomic barriers |
| BC | |
 |
1. Most are not FDA-approved2. Meal content not included in calculation |
| RT-CGM | |
|
1. Cost2. Low adherence rates |
| SAP | |
|
1. Cost2. 2 insertion sites |
| LGTS | |
|
1. Cost2. 2 insertion sites3. Limited number of studies |
| LGPS | |
|
1. Cost2. 2 insertion sites3. Limited number of studies |
LGPS systems are approved in the European Union but not yet by the US Food and Drug Administration.